Stocktoria
Beta Bionics, Inc. BBNX
Nasdaq · stock · Surgical & Medical Instruments & Apparatus · website · IPO 2025-01-30
Beta Bionics, Inc. financials (annual)
Bars are annual figures from 2023 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $100.3M | $65.1M | $12.0M |
| Gross profit | $55.5M | $35.9M | $6.3M |
| R&D expense | $34.8M | $26.2M | $17.9M |
| Operating income | -$71.7M | -$45.3M | -$35.9M |
| Income tax | $0 | $0 | — |
| Net income | -$73.2M | -$54.8M | -$44.1M |
| EPS (diluted) | $-1.81 | $-8.60 | $-8.31 |
| Operating cash flow | -$50.9M | -$48.3M | -$32.4M |
| Free cash flow | -$56.2M | -$51.7M | -$32.8M |
| Cash & equivalents | $31.6M | $30.4M | $26.6M |
| Inventory | $21.7M | $13.3M | $1.2M |
| Total assets | $328.7M | $149.6M | $110.0M |
| Total liabilities | $41.1M | $73.6M | $51.4M |
| Shareholders' equity | $287.6M | -$245.4M | -$203.1M |
Growth · year-over-year · Revenue CAGR 189.1%
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue growth | +53.9% | +442.9% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.